) recently announced that French regulatory authorities have
approved the initiation of a phase I/II trial for its oral
hepatitis C virus (HCV) infection candidate, BL-8020.
The open-label phase I/II trial will be conducted across two
sites in France and will enroll patients infected with HCV who
have either failed or relapsed after undergoing treatment with
the current standard-of-care. The trial will evaluate the
efficacy, safety and tolerability of the candidate in
HCV-infected patients. BioLineRx expects to report interim
results from the study by year-end.
We believe HCV infection represents a huge commercial opportunity
for BioLineRx. As per data from a 2011 report from Decision
Resources, approximately 180 million people are suffering from
chronic HCV infection globally. The global HCV infection market
is expected to be worth $20 billion by 2020 as opposed to $6
billion in 2011.
Apart from BL-8020, other interesting candidates in BioLineRx's
pipeline include BL-1020 for schizophrenia (phase II/III),
BL-1040 for preventing pathological cardiac remodeling following
a myocardial infarction (pivotal CE-Mark registration trial), and
BL-5010 for non-surgical removal of skin lesions (phase I/II
study complete). We are impressed with the company's efforts to
develop its pipeline.
BioLineRx, a biopharmaceutical company, carries a Zacks Rank #3
(Hold). Biopharma companies that currently look more attractive
Array BioPharma Inc.
). While Cytokinetics is a Zacks Rank #1 (Strong Buy) stock,
Array BioPharma carries a Zacks Rank #2 (Buy). Another pharma
stock that looks attractive is
Osiris Therapeutics, Inc.
). Osiris is also a Zacks Rank #1 stock.
ARRAY BIOPHARMA (ARRY): Free Stock Analysis
BIOLINE RX LTD (BLRX): Get Free Report
CYTOKINETCS INC (CYTK): Free Stock Analysis
OSIRIS THERAPTC (OSIR): Free Stock Analysis
To read this article on Zacks.com click here.